نتایج جستجو برای: asunaprevir

تعداد نتایج: 282  

2016
Jun Itakura Masayuki Kurosaki Chitomi Hasebe Yukio Osaki Kouji Joko Hitoshi Yagisawa Shinya Sakita Hiroaki Okushin Takashi Satou Hiroyuki Hisai Takehiko Abe Keiji Tsuji Takashi Tamada Haruhiko Kobashi Akeri Mitsuda Yasushi Ide Chikara Ogawa Syotaro Tsuruta Kouichi Takaguchi Miyako Murakawa Yasuhiro Asahina Nobuyuki Enomoto Namiki Izumi

BACKGROUNDS & AIMS We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus genotype 1b infection. METHODS This is a nationwide multicenter study conducted by the Japanese Red Cross Liver Study Group. Th...

2017
Hideki Fujii Atsushi Umemura Taichiro Nishikawa Kanji Yamaguchi Michihisa Moriguchi Hideki Nakamura Kohichiroh Yasui Masahito Minami Saiyu Tanaka Hiroki Ishikawa Hiroyuki Kimura Shiro Takami Yasuyuki Nagao Toshihide Shima Yoshito Itoh

AIM To investigate daclatasvir (DCV) and asunaprevir (ASV) efficacy in hepatitis C (HCV) patients, with respect to resistance-associated substitutions (RASs). METHODS A total of 392 HCV-infected patients from multiple centers were included in this study. We evaluated their clinical courses and sustained virologic responses (SVR) according to pretreatment factors (gender, age, history of inter...

Journal: :Pharmaceutical Sciences 2021

Background: Drug repurposing is the fastest effective method to provide treatment for coronavirus disease (COVID-19). Drugs that targeting a closely related virus with similar genetic material such as hepatitis C (HCV) and more specifically viral protease would be an excellent choice. Methods: In this study, we carried out virtual screening fifteen anti HCV drugs against COVID-19 main using com...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید